Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.79M Sell
116,067
-321
-0.3% -$8.4K 1.65% 23
2026
Q1
$3.27M Sell
116,388
-4,475
-4% -$119K 2.14% 20
2025
Q4
$3.01M Sell
120,863
-1,430
-1% -$36.1K 2.04% 21
2025
Q3
$3.12M Buy
122,293
+800
+0.7% +$19.7K 1.94% 24
2025
Q2
$2.94M Sell
121,493
-325
-0.3% -$7.58K 2.08% 19
2025
Q1
$3.09M Sell
121,818
-1,604
-1% -$42K 2.45% 20
2024
Q4
$3.27M Sell
123,422
-5,600
-4% -$152K 2.39% 18
2024
Q3
$3.73M Sell
129,022
-3,435
-3% -$100K 2.93% 13
2024
Q2
$3.71M Buy
132,457
+165
+0.1% +$4.54K 2.82% 13
2024
Q1
$3.67M Sell
132,292
-1,280
-1% -$35.5K 2.81% 13
2023
Q4
$3.85M Buy
133,572
+119,262
+833% +$3.61M 3.34% 11
2023
Q3
$475K Buy
14,310
+3,160
+28% +$112K 0.44% 36
2023
Q2
$409K Sell
11,150
-800
-7% -$31.1K 0.39% 36
2023
Q1
$488K Sell
11,950
-69,775
-85% -$3.01M 0.53% 27
2022
Q4
$4.19M Buy
+81,725
New +$3.92M 4.44% 5

Other funds holding PFE

Ellerson Group's PFE Position: Q2 2026 in Review

Ellerson Group reduced its Pfizer (PFE) stake by 0.28% in Q2 2026, selling an estimated $8.4K and leaving 116,067 shares worth $2.79M. The position accounts for 1.65% of the portfolio, ranked #23.

Ellerson Group first reported a position in PFE in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.19M in Q4 2022. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Ellerson Group held 116,067 shares of Pfizer worth $2.79M as of Q2 2026.
  • Ellerson Group sold 321 Pfizer shares in Q2 2026, an estimated $8.4K.
  • Pfizer made up 1.65% of Ellerson Group's portfolio in Q2 2026, its #23 holding.
  • Ellerson Group first reported a position in Pfizer in Q4 2022 and has held it in 15 quarters since.
  • Ellerson Group's Pfizer position peaked at $4.19M in Q4 2022.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Ellerson Group's 13F filing for Q2 2026, filed 31 Jul 2026.